Precision BioSciences nabbed $25.6 million in its initial funding round thanks to the likes of Fidelity Biosciences, Amgen Ventures, Baxter Ventures and Osage University Partners in support of its ARCUS gene editing platform. "We're an older genome editing company with the latest genome-editing technology," said the Duke spinout's CEO Matthew Kane. "ARCUS is a fully synthetic nuclease that we've developed here at Precision to overcome some of the key hurdles faced by the earlier technologies." The large sum of money dished out to the company demonstrates the wave of interesting in one of biotech's newest research paradigms. More